Table. 2.

Inhibition effect of SARS-CoV-2 and survival cell ratio by concentration in experimental group

Substance Concentration
(µM)
Inhibition-normalized infection ratio Cell number to mock (%) IC50 CC50 SI
1st 2nd 1st 2nd
PPAR-γ agonist-1 50.00 0.07 -0.36 101.20 101.37 >50 >50 1.0
25.00 -1.42 1.80 101.18 101.57
12.50 -1.27 2.14 102.75 102.43
6.25 0.33 1.29 104.11 99.55
3.13 1.85 0.29 101.00 98.76
1.56 1.09 0.41 103.81 98.93
0.78 0.02 -0.22 103.12 96.27
0.39 1.16 1.26 100.88 101.20
0.20 1.03 -0.52 100.12 101.42
0.10 0.82 -0.93 102.26 100.86
PPAR-γ agonist-2 50.00 3.19 13.50 102.75 108.47 >50 >50 1.0
25.00 1.57 3.98 106.69 104.77
12.50 3.00 4.83 107.19 108.02
6.25 0.56 3.59 106.33 109.06
3.13 0.86 5.18 105.61 105.93
1.56 2.34 1.92 106.87 107.80
0.78 4.01 4.17 109.95 107.04
0.39 1.15 1.46 106.69 105.91
0.20 2.76 0.50 105.49 107.14

PPAR-γ, peroxisome proliferator-activated receptors-gamma; IC, inhibitory concentration; CC, cytotoxic concentration; SI, selectivity index.

Korean J Fam Pract 2021;11:312~321 https://doi.org/10.21215/kjfp.2021.11.4.312
© KJFP